Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
We also explored the possibility that this PKC activating pr
2025-01-16

We also explored the possibility that this PKC-θ activating protein could operate on the auto-phosphorylation process of the kinase, a specific event accompanying PKC activation [32]. The heated PKC-θ immunoprecipitate from metaphasic cells was then added to PKC-θ isolated both from interphasic or m
-
br Mechanism of action In general the main targets for
2025-01-16

Mechanism of action In general, the main targets for antifungal drug development are cell wall polymer (glucans, chitin, mannoproteins), cell membrane (especially ergosterol) biosynthesis, DNA and protein synthesis (topoisomerases, nucleases, elongation factors and myristoylation), and signal tra
-
Various antiangiogenic drugs have been analyzed over the
2025-01-16

Various antiangiogenic drugs have been analyzed over the last few years; noteworthy, bevacizumab, a monoclonal antibody against VEGF-A, alone or in combination with cytotoxic agents showed interesting results in terms of radiographic response rates and progression-free survival in initial phase 2 st
-
A previous review article suggested different washout interv
2025-01-16

A previous review article suggested different washout intervals based on specific clinical contexts [4]. While no consensus was reached for the optimal interval between last dose of BV and surgery for CRLM, the authors of the review suggested waiting 6 to 8 weeks after BV before surgery, particularl
-
A phase I trial has recently evaluated enzalutamide an
2025-01-16

A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with
-
Another class of AMPK regulator is peptidyl prolyl
2025-01-16

Another class of AMPK regulator is peptidyl-prolyl cis/trans isomerase (PPIase) NIMA-interacting 1 (Pin1), which binds to a number of proteins and regulates oncogenesis and metabolic diseases (Khanal et al., 2013; Zhou and Lu, 2016). Pin1 has been shown to bind to and inhibit AMPK; therefore, at lea
-
br Conclusion These studies broadly
2025-01-16

Conclusion These studies broadly demonstrate that dopamine and endocannabinoid signaling in the NAc can have diverse effects on AMPAR-mediated synaptic function depending on previous psychostimulant experience. Here, we examined mechanisms underlying the depotentiation of AMPAR-mediated synaptic
-
These results validate the docked
2025-01-16

These results validate the docked pose of the ALR2-3e complex in comparison to the docked complex of the ALR2-4c complex of which the compound docked completely out of the binding pocket of ALR2 (). This concludes to that the removal of the acetic GANT 58 moiety leads to inactive or weakly active
-
Unexpectedly under pathological pain conditions inhibition o
2025-01-16

Unexpectedly, under pathological pain conditions, inhibition of spinal glutamate transporter activity can produce antinociceptive effects. For example, intrathecal injection of the transportable inhibitor trans-pyrrolidine-2,4-dicarboxylic Lauric Acid (t-PDC) or antisense oligonucleotides reduced no
-
APPL was the first adaptor
2025-01-16

APPL1 was the first adaptor protein identified that interacts directly with adiponectin receptors [18]. A two-hybrid study by Dong and colleagues revealed that the C-terminal extracellular domain of AdipoR1 interacts with adiponectin, whereas the N-terminal cytoplasmic domain of AdipoR1 interacts wi
-
The obtained results indicate that even when the impairment
2025-01-16

The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate
-
br Experimental procedures Adk tg Adktm tg UbiAdk
2025-01-16

Experimental procedures Adk-tg (Adktm1−/−:tg(UbiAdk) mice were created by breeding a loxP-flanked Adk transgene under the control of a human ubiquitin promoter into ADK knockout mice (Fedele et al., 2005,). Fb-Adk-def (Adktm1−/−:tg(UbiAdk):Emx1-Cre-tg3) mice were generated by pairing Emx1-Cre-tg3
-
br New AMPK activators Fenofibrate is a
2025-01-16

New AMPK activators Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal fu
-
br Structure of V ATPase V ATPase is a highly
2025-01-15

Structure of V-ATPase V-ATPase is a highly conserved multi-subunit enzyme that uses energy from ATP hydrolysis to transport protons across membranes [2], [3], [4]. It consists of two major functional domains, V1 and V0 (Fig. 1). The former has eight different subunits (A, B, C, D, E, F, G, and H)
-
Echinocandin resistance is systematically associated with po
2025-01-15

Echinocandin resistance is systematically associated with point mutations in either FSK1 or FSK2 genes [7], [104]. These mutations are located in two different not spot regions of these genes named HS1 and HS2. Hot spot mutations have been reported in C. albicans, C. glabrata, C. tropicalis, C. krus
13693 records 39/913 page Previous Next First page 上5页 3637383940 下5页 Last page